Pneumocystis pneumonia remains the most prevalent opportunistic infection in patients infected with the human immunodeficiency virus (HIV). First identified as a protozoan nearly 100 years ago and reclassified as a fungus in 1988, pneumocystis cannot be propagated in culture. Few treatment options exist for patients with pneumocystis pneumonia. The number of patients who are receiving chronic immunosuppressive medication or who have an altered immune system and are thus at risk for pneumocystis pneumonia is rapidly growing. Although the prevalence of the acquired immunodeficiency syndrome (AIDS) has decreased in the Western hemisphere owing to the routine use of highly active antiretroviral therapy (HAART), many patients worldwide do not have the resources for HAART. The increased reservoir for infection among such patients leads to concern that resistance to trimethoprim–sulfamethoxazole, the most common treatment for pneumocystis pneumonia, will emerge, although this has yet to happen. The application of molecular techniques to the study of pneumocystis has provided new insights into the complex cell biology of this fungus. In this article we summarize advances that have resulted from studies of the cell biology, biochemistry, and genetics of pneumocystis in the past several years and include recommendations for the diagnosis of pneumocystis pneumonia, as well as for prophylaxis and treatment.

**Clinical Features of Pneumocystis Pneumonia**

Pneumocystis pneumonia is often the AIDS-defining illness in patients infected with HIV, occurring most frequently when the T-helper cell count (CD4+) is less than 200 cells per cubic millimeter. Common symptoms of pneumocystis pneumonia include the subtle onset of progressive dyspnea, nonproductive cough, and low-grade fever. Acute dyspnea with pleuritic chest pain may indicate the development of a pneumothrax. Physical examination typically reveals tachypnea, tachycardia, and normal findings on lung auscultation.

Patients with AIDS and pneumocystis pneumonia have a significantly increased number of pneumocystis organisms in their lungs, with fewer neutrophils, than do patients with pneumocystis pneumonia in the absence of AIDS. This greater organism burden results in a higher diagnostic yield of induced sputum and bronchoalveolar-lavage fluid to confirm pneumocystis pneumonia in patients with AIDS as compared with other conditions associated with immunosuppression. The smaller number of inflammatory cells in patients with AIDS-related pneumocystis pneumonia also correlates with better oxygenation and survival as compared with pneumocystis pneumonia in patients without AIDS. Patients with mild symptoms of pneumocystis pneumonia can often be treated as outpatients with the use of oral therapy and close follow-up. However, patients with significant hypoxemia should be hospitalized for the administration of intravenous therapy. The development of worsening pneumonia with respiratory fail-
ure in these patients is the most common reason for admission to an intensive care unit. Among most patients with AIDS and pneumocystis pneumonia, the mortality rate is 10 to 20 percent during the initial infection, but the rate increases substantially with the need for mechanical ventilation.\(^\text{10}\)

Patients who have pneumocystis pneumonia without AIDS typically present with an abrupt onset of respiratory insufficiency that may correlate with a tapered or increased dosage of immunosuppressant medications.\(^\text{11,12}\) Affected patients have more neutrophils and fewer pneumocystis organisms in their lungs during an episode of pneumocystis pneumonia than do patients with AIDS who have pneumocystis pneumonia.\(^\text{9}\) The mortality rate among patients with pneumocystis pneumonia in the absence of AIDS is 30 to 60 percent, depending on the population at risk, with a greater risk of death among patients with cancer than among patients undergoing transplantation or those with connective-tissue disease.\(^\text{2,13}\)

Typical radiographic features of pneumocystis pneumonia are bilateral perihilar interstitial infiltrates that become increasingly homogeneous and diffuse as the disease progresses (Fig. 1).\(^\text{14}\) Less common findings include solitary or multiple nodules, upper-lobe infiltrates in patients receiving aerosolized pentamidine, pneumatoceles, and pneumothorax. Pleural effusions and thoracic lymphadenopathy are rare. When chest radiographic findings are normal, high-resolution computed tomography, which is more sensitive than chest radiography, may reveal extensive ground-glass attenuation or cystic lesions.\(^\text{15}\)

**Diagnosis of Pneumocystis Infection**

Pneumocystis pneumonia may be difficult to diagnose owing to nonspecific symptoms and signs, the use of prophylactic drugs in the treatment of HIV-infected patients, and simultaneous infection with multiple organisms (such as cytomegalovirus) in an immunocompromised host. The diagnosis of pneumocystis pneumonia therefore requires microscopical examination in order to identify pneumocystis from a clinically relevant source such as specimens of sputum, bronchoalveolar fluid, or lung tissue, because pneumocystis cannot be cultured (Fig. 2).\(^\text{16}\)

Sputum induction with hypertonic saline has a diagnostic yield of 50 to 90 percent and should be the initial procedure used to diagnose pneumocystis pneumonia, particularly in patients with AIDS.\(^\text{17}\) If the initial specimen of induced sputum is negative for pneumocystis, then bronchoscopy with bronchoalveolar lavage should be performed. Transbronchoscopic or surgical lung biopsy is rarely needed.\(^\text{18}\) Trophic forms can be detected with modified Papanicolaou, Wright–Giemsa, or Gram–Weigert stains. Cysts can be stained with Gomori methenamine silver, cresyl echt violet, toluidine blue O, or calcofluor white. Monoclonal antibodies for detecting pneumocystis have a higher sensitivity and specificity in induced-sputum samples than conventional tinctorial stains have, but the difference is much less in bronchoalveolar-lavage fluid.\(^\text{19,20}\) An advantage of monoclonal antibodies is their ability to stain both trophic forms and cysts, which is important because the trophic forms are generally more abundant during pneumocystis pneumonia.

The use of the polymerase chain reaction (PCR) to detect pneumocystis nucleic acids has been an active area of research. PCR has been shown to have greater sensitivity and specificity for the diagnosis of pneumocystis pneumonia from specimens of induced sputum and bronchoalveolar-lavage fluid than conventional staining when PCR primers for the gene for pneumocystis mitochondrial large-subunit ribosomal RNA (rRNA) are used.\(^\text{21,22}\) In patients with positive PCR results in bronchoalveolar-lavage fluid or sputum but with negative smears, clinical management of the disease remains a challenge. However, we recommend treatment of these patients if immunosuppression is ongoing.\(^\text{23}\) PCR testing of serum samples is not yet useful.\(^\text{24}\)

Although an elevated serum lactate dehydrogenase level has been noted in patients with pneumocystis pneumonia, it is likely to be a reflection of the underlying lung inflammation and injury rather than a specific marker for the disease.\(^\text{25}\) Lower levels of plasma S-adenosylmethionine were observed in seven patients with confirmed pneumocystis pneumonia than in patients with other pulmonary infections, but the usefulness of this test will need to be confirmed in a larger cohort of patients.\(^\text{26}\)

**Prophylaxis and Treatment of Pneumocystis Pneumonia**

Primary prophylaxis against pneumocystis pneumonia in HIV-infected adults, including pregnant
women and patients receiving HAART, should begin when the CD4+ count is less than 200 cells per millimeter or if there is a history of oropharyngeal candidiasis. Medications recommended for prophylaxis are listed in Table 1. Patients who have had previous episodes of pneumocystis pneumonia should receive lifelong secondary prophylaxis, unless reconstitution of the immune system occurs as a result of HAART. Primary or secondary prophylaxis should be discontinued in HIV-infected patients who have had a response to HAART, as shown by an increase in the CD4+ cell count to more than 200 cells per cubic millimeter for a period of three months. Prophylaxis should be reintroduced if the CD4+ count falls to less than 200 cells per cubic millimeter.

Patients who are not infected with HIV but are receiving immunosuppressive medications or who have an underlying acquired or inherited immunodeficiency should receive prophylaxis against pneumocystis pneumonia. In a retrospective series, a corticosteroid dose that was the equivalent of 16 mg of prednisone or more for a period of eight weeks was associated with a significant risk of pneumocystis pneumonia in patients who did not have AIDS. Similar observations have been noted in patients with cancer or with connective-tissue disease that was treated with corticosteroids. The notion that trimethoprim–sulfamethoxazole is contraindicated for pneumocystis pneumonia prophylaxis in patients treated with methotrexate may be outdated, because in patients treated with up to 25 mg of methotrexate per week who received prophylaxis, severe myelosuppression did not develop. Such patients need to receive folate supplementation (1 mg per day), or leucovorin on the day after receiving methotrexate, and careful monitoring of the results of complete blood counts and liver-function tests is necessary.

Medications used to treat pneumocystis pneumonia are listed in Table 2. Trimethoprim–sulfamethoxazole is most effective in treating severe pneumocystis pneumonia. Unfortunately, adverse effects are common, and patients with known allergies to sulfis cannot tolerate this therapy. Corticosteroids are of benefit in HIV-infected patients with pneumocystis pneumonia who have hypoxemia (the partial pressure of arterial oxygen while the patient is breathing room air is under 70 mm Hg or the alveolar–arterial gradient is above 35). Such patients should receive prednisone at a dose of 40 mg twice daily for five days, then 40 mg daily on days 6 through 11, and then 20 mg daily on days 12 through 21. In patients without AIDS but with severe pneumocystis pneumonia, a dose of 60 mg or more of prednisone daily resulted in a better outcome than lower doses of prednisone.

The transmission of pneumocystis is not fully understood, nor has its environmental niche been identified. For decades, the theory of the reactivation of latent pneumocystis infection — which held that pneumocystis remained latent within a person and caused disease when the immune system failed — was popular. Now there is evidence that person-to-person transmission is the most likely mode of acquiring new infections, although acquisition from environmental sources may also occur. In addition, people who are not infected may be asympto-
tomatic carriers of pneumocystis. Although the results of studies in animals and humans favor airborne transmission, respiratory isolation for patients with pneumocystis pneumonia is not currently recommended.

The emerging resistance to trimethoprim–sulfamethoxazole is being investigated with the use of molecular techniques to study mutations in the dihydropteroate synthase gene, which encodes the enzyme inhibited by dapsone and sulfamethoxazole. Several reports have implicated specific mutations in dihydropteroate synthase that are associated with the failure of prophylaxis and treatment, an increase in the risk of death, and the selection of dihydropteroate synthase mutations by exposure of patients to sulfā-containing drugs. Because most patients harboring pneumocystis that contains dihydropteroate synthase mutations still have a response to treatment with trimethoprim–sulfamethoxazole, further research is necessary to determine the importance of these mutations and whether the geographic variation of pneumocystis infection and of other mutations contribute when clinical treatment fails.

**The Biology of the Parasite**

The full identification and classification of pneumocystis took many decades. Pneumocystis organisms were first identified by Carlos Chagas in the early 20th century, with the use of a guinea-pig mod-

---

**Figure 2. Detection of Pneumocystis Forms with the Use of Different Stains.**

Panel A shows typical pneumocystis cyst forms in a bronchoalveolar-lavage specimen stained with Gomori methenamine (×100). Thick cyst walls and some intracystic bodies are evident. Wright–Giemsa staining can be used for rapid identification of trophic forms of the organisms within foamy exudates, as shown in Panel B (arrows), in bronchoalveolar-lavage fluid or induced sputum but usually requires a high organism burden and expertise in interpretation (×100). Calcofluor white is a fungal cyst-wall stain that can be used for rapid confirmation of the presence of cyst forms, as shown in Panel C (×400). Immunofluorescence staining, shown in Panel D, can sensitively and specifically identify both pneumocystis trophic forms (arrowheads) and cysts (arrows) (×400).
el of trypanosome infection, and subsequently by Antonio Carinii, in infected rat lungs.4,5 Both investigators believed they had identified new forms of trypanosomes. Several years later, however, the Delanoës recognized that Chagas and Carinii had identified a new species with a unique tropism for the lung; hence, the new species was named *Pneumocystis carinii*.3

*Pneumocystis* was initially misclassified as a protozoan on the basis of the morphologic features of the small trophic form, the larger cyst form, the development of up to eight progeny within the cyst, and the rupture of the cyst to release new trophic forms. In 1988, an analysis of the small rRNA subunit from pneumocystis pneumonia established a phylogenetic linkage to the fungal kingdom, and all subsequent genomic information has corroborated pneumocystis’s home within the ascomycetous fungi.6

Pneumocystis organisms have been identified in virtually every mammalian species. In humans, serologic surveys have shown nearly universal seropositivity to pneumocystis in tested populations by two years of age.40 Pneumocystis organisms encompass a family of organisms that have a range of genetic characteristics and that are host-specific. For example, the pneumocystis that infects humans, which was recently renamed *P. jirovecii*, cannot infect the rat, and vice versa.41 The reason for this stringent host specificity is unclear. The use of binomial nomenclature for human pneumocystis may be of less importance currently, given that visualization of the organism is required for the diagnosis of pneumonia.42,43 When PCR has been applied to pneumocystis pneumonia in humans, only *P. jirovecii* has been found, and for that reason, specifying the name of the species will become important only if additional species of pneumocystis are found to infect humans.

The major obstacle to studying pneumocystis is the inability to achieve sustained propagation of the organism outside the host lung.48 Many investigators have attempted to cultivate pneumocystis using a variety of techniques, but none have been successful. Cell-free systems that use media preparations for growing protozoa, bacteria, and fungi and tissue-culture systems in which a variety of cell lines are used have not been successful. Attempts to simulate the intraalveolar environment and to supplement media with numerous additives, such as surfactant, lung homogenates, or various chemical compounds, have also proved unhelpful. Until the organism can be cultivated in vitro, the infected-animal model of pneumocystis pneumonia will remain the source of organisms for study.

Pneumocystis has a unique tropism for the lung, where it exists primarily as an alveolar pathogen without invading the host. In rare cases, pneumocystis disseminates in the setting of severe underlying immunosuppression or overwhelming infection.44 Microscopically, one can identify the small trophic forms (1 to 4 µm in diameter) and the larger cysts (8 µm in diameter). Electron microscopic studies have shown three stages of precysts, the early, intermediate, and late stages (Fig. 3).45-47 The trophic forms are predominantly haploid, though diploid forms also exist, whereas the cyst contains two, four, or eight nuclei.48

The availability of molecular techniques has led...
Table 2. Treatment of Pneumocystis Pneumonia.

<table>
<thead>
<tr>
<th>Drug</th>
<th>Dose</th>
<th>Route</th>
<th>Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td>Trimethoprim–sulfamethoxazole</td>
<td>15–20 mg/kg/day</td>
<td>Oral or intravenous</td>
<td>First choice</td>
</tr>
<tr>
<td></td>
<td>75–100 mg/kg/day</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>daily in divid-</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>ed doses</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Primaquine plus clindamycin</td>
<td>30 mg daily</td>
<td>Oral</td>
<td>Alternate choice</td>
</tr>
<tr>
<td></td>
<td>600 mg three times daily</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Atovaquone</td>
<td>750 mg two times daily</td>
<td>Oral</td>
<td>Alternate choice</td>
</tr>
<tr>
<td>Pentamidine</td>
<td>4 mg/kg daily</td>
<td>Intra-</td>
<td>Alternate choice</td>
</tr>
<tr>
<td></td>
<td>600 mg daily</td>
<td>venous</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Aerosol</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

To major advances in our understanding of the biology of pneumocystis in the past several years. Key molecules have been identified in the mitotic cell cycle, cell-wall assembly, signal-transduction cascades, and metabolic pathways. The use of heterologous fungal systems to study the expression of pneumocystis genes has helped this effort, but standard biochemical and genetic analysis within the organism will be necessary to confirm the function of these molecules, once it becomes possible to culture pneumocystis.

The first specific molecule identified from pneumocystis was a glycoprotein with an apparent molecular mass under reducing conditions of 95 to 120 kD.49,50 It is a 120 kD glycoprotein A, or major surface glycoprotein, this molecule is heavily glycosylated with mannose-containing carbohydrates and has an integral role in the attachment of pneumocystis to host cells.50-54 Glycoprotein A consists of a mixture of proteins that are encoded by a family of genes in pneumocystis, but only a single glycoprotein A is expressed by pneumocystis at any one time.55,56 This surface glycoprotein is immunogenic and antigenically distinct in every form of pneumocystis infecting various mammalian hosts.49,57,58 The major component of the cyst cell wall is beta-1,3-glucan, which is composed of homopolymers of glucose molecules with a beta-1,3-linked carbohydrate core and side chains of beta-1,6- and beta-1,4-linked glucose.59

The cyst wall also contains chitins and other complex polymers, including melanins. In addition to providing the cell wall with stability, pneumocystis glucan is at least partly responsible for the marked inflammatory response in the lungs of the infected host.60,61 The pneumocystis beta-1,3-glucan synthetase gene, GSC1, mediates the polymerization of uridine 5’-diphosphoglucose into beta-1,3-glucan.62 Inhibitors of beta-1,3-glucan synthetase are effective in clearing the cystic forms of pneumocystis from the lungs of infected animals.63,64 Perturbation of the pneumocystis cell-wall assembly represents an attractive target for the treatment of pneumocystis pneumonia, because the biosynthetic machinery for generating glucan is not present in mammals.

Because currently it is not possible to grow pneumocystis outside an infected host, the functional analysis of the pneumocystis cell cycle and of signal-transduction molecules has been performed with the use of heterologous expression in related fungi. The pneumocystis cdc2 cyclin-dependent kinase, cdc13 B-type cyclin, and cdc25 mitotic phosphatase all complement the function of cell-cycle regulation in yeast that harbor mutations for these genes.65-67 Fungi use mitogen-activated protein kinase signal-transduction cascades to regulate the cellular responses for mating, environmental stress, cell-wall integrity, and pseudohyphal or filamentous growth. Mitogen-activated protein kinase molecules homologous to those found in mating and cell-wall-integrity pathways have been identified in pneumocystis.68-70 The gene encoding pneumocystis mitogen-activated protein kinase (PCM) functionally complements pheromone signaling in Saccharomyces cerevisiae.70 Furthermore, the finding of enhanced activity of PCM in trophic forms as compared with that in cysts suggests that the trophic forms use this pathway for transitions in the life cycle of the organism.70 In the cell-wall integrity pathway, the kinases Bck1 and Mpk1 function in response to elevated temperature.68,71,72

The trophic forms of pneumocystis adhere tightly to the alveolar epithelium as the infection becomes established. The binding of pneumocystis to epithelial cells in the lung activates specific signaling pathways in the organisms, including the gene encoding PCSTE20 kinase, which signal responses for mating and proliferation in fungal organisms.73 Other signaling molecules, including the putative pheromone receptors, heterotrimeric G-protein subunits, and transcription factors, have also been identified.74-76

Investigators are further evaluating specific molecules within pneumocystis as potential drug targets. These molecules include dihydrofolate reductase, the product of which is the target of trimethoprim; thymidylate synthase; inosine mono-
phosphate dehydrogenase, which is inhibited by mycophenolic acid; \( S \)-adenosyl-L-methionine:sterol C-24 methyl transferase, which is involved in the biosynthesis of sterol; and lanosterol 14\( \alpha \)-demethylase, the target enzyme of azole antifungal compounds.\(^{77-80}\) With work on the cloning of the pneumocystis genome continuing, the identification of additional treatment targets is anticipated.

**HOST RESPONSE TO PNEUMOCYSTIS INFECTION**

Effective inflammatory responses in the host are required to control pneumocystis pneumonia. Exuberant inflammation, however, also promotes pulmonary injury during infection. Severe pneumocystis pneumonia is characterized by neutrophilic lung inflammation that may result in diffuse alveolar damage, impaired gas exchange, and respiratory failure. Indeed, respiratory impairment and death are more closely correlated with the degree of lung inflammation than with the organism burden in pneumonia.\(^9\) Although patients with neutropenia occasionally become infected with pneumocystis, they do not appear to be inordinately predisposed to this infection as compared with other groups of immunosuppressed patients.

**LYMPHOCYTE RESPONSES TO PNEUMOCYSTIS**

Immune responses directed against pneumocystis involve complex interactions between CD4+ T lymphocytes, alveolar macrophages, neutrophils, and the soluble mediators that facilitate the clearance of the infection. In particular, the activity of CD4+ T cells is pivotal in the host’s defenses against pneumocystis, in both animals and humans, and the risk of infection increases with a CD4+ count of less than 200 per cubic millimeter.\(^{7,81}\) CD4+ cells function as memory cells that orchestrate the host’s inflammatory responses by means of the recruitment and activation of other immune effector cells, including monocytes and macrophages, to attack the organism. Mice with severe combined immunodeficiency (SCID) lack functional T and B lymphocytes, and spontaneous pneumocystis infection may develop in them by three weeks of age, providing an excellent model for understanding the function of lymphocytes in this disease.\(^82\) SCID mice have progressive pneumocystis infection, despite the presence of otherwise functional macrophages and neutrophils.\(^82,83\) When the immune system is reconstituted with the use of CD4+ spleen cells, however, the mice regain the ability to clear infection effectively.\(^84,85\)

The mechanisms by which CD4+ cells mediate a defense against pneumocystis have only begun to emerge in recent years. Macrophage-derived tumor necrosis factor \( \alpha \) (TNF-\( \alpha \)) and interleukin-1 are believed to be necessary for initiating pulmo-
nary responses to pneumocystis infection that are mediated by CD4+ cells. The cells proliferate in response to pneumocystis antigens and generate cytokine mediators, including lymphotactin and interferon gamma. Lymphotactin, a chemokine, acts as a potent chemoattractant for further lymphocyte recruitment in pneumocystis pneumonia. Interferon gamma strongly activates the macrophage production of TNF-α, superoxides, and reactive nitrogen species, each of which is implicated in the host defense against pneumocystis. Aerosolized interferon gamma reduces the intensity of infection in rats infected with pneumocystis, regardless of the degree of CD4+ depletion.

Although T lymphocytes are essential for the clearance of pneumocystis, data suggest that T-cell responses may also result in substantial pulmonary impairment during pneumocystis pneumonia. For instance, in SCID mice infected with pneumocystis, normal oxygenation and lung function occur despite active infection until the late stages of the disease. When the immune systems in these animals are reconstituted with the use of intact spleen cells, an intense T-cell–mediated inflammatory response ensues, resulting in substantially impaired gas exchange.

In the absence of brisk lung inflammation, pneumocystis has little direct effect on pulmonary function. In a similar manner, in patients who have undergone bone marrow transplantation the clinical onset of pneumocystis pneumonia and of most marked alterations in lung function occur during engraftment. Pneumocystis pneumonia also results in the marked accumulation of CD8+ T lymphocytes in the lung.

MACROPHAGES IN HOST DEFENSE AGAINST PNEUMOCYSTIS

Alveolar macrophages are the principal phagocytes mediating the uptake and degradation of organisms in the lung. When there are no opsonins in the epithelial-lining fluid, the uptake of pneumocystis is mediated mainly through the macrophage mannose receptors, pattern-recognition molecules that interact with the surface mannoprotein, glycoprotein A. After they have been taken up by macrophages, pneumocystis organisms are incorporated into phagolysosomes and degraded.

The function of macrophages is impaired in patients with AIDS, malignant disease, or both, resulting in the reduced clearance of pneumocystis. In macrophage-depleted animals the resolution of pneumocystis infection is impaired. Macrophages produce a large variety of proinflammatory cytokines, chemokines, and eicosanoid metabolites in response to phagocytosis of pneumocystis. Although these mediators participate in eradicating pneumocystis, they also promote pulmonary injury.

CYTOKINE AND CHEMOKINE NETWORKS

TNF-α has important effects during pneumocystis pneumonia. The clearance of pneumocystis is delayed when TNF-α is neutralized by antibodies or inhibitors in animals with pneumocystis pneumonia. TNF-α promotes the recruitment of neutrophils, lymphocytes, and monocytes. Although their recruitment is important for clearance of the organisms, these cells injure the lung by releasing oxidants, cationic proteins, and proteases. TNF-α also induces the production of other cytokines and chemokines, including interleukin-8 and interferon gamma, which stimulate the recruitment and activation of inflammatory cells during pneumocystis pneumonia.

The cell wall of pneumocystis contains abundant beta-glucans, and studies have confirmed that the production of TNF-α by alveolar macrophages is mediated by recognition of the beta-glucan components of pneumocystis. Macrophages display several potential receptors for glucans, including CD11b/CD18 integrin (CR3), dectin-1, and toll-like receptor 2. The activation of macrophages by pneumocystis is augmented by proteins in the host such as vitronectin and fibronectin that bind the glucan components on the organism.

The cysteine–X amino acid–cysteine chemokines, such as interleukin-8, macrophage-inflamatory protein 2, and the interferon-inducible protein of 10 kD, which are potent chemoattractants for neutrophils, are important during pneumocystis infection. Interleukin-8 is correlated with both neutrophil infiltration of the lung and impaired gas exchange during severe pneumocystis pneumonia. Furthermore, the level of interleukin-8 in bronchoalveolar-lavage fluid may serve as a predictor of severe respiratory compromise and death from the disease. Isolated pneumocystis beta-glucan stimulates alveolar macrophages and alveolar epithelial cells to produce marked quantities of macrophage inflammatory protein 2. The neutrophils recruited into the lungs release reactive oxidant species, proteases, and cationic proteins, which directly injure capillary endothelial cells and alveolar epithelial cells.
Trophic forms adhere tightly to type I alveolar cells through interdigitation of their membranes with those of the host. The binding of pneumocystis to the epithelium is facilitated by interactions of proteins in the host, such as fibronectin and vitronectin, that bind to the surface of pneumocysts and mediate the attachment to integrin receptors present on the alveolar epithelium. In infected tissues, type I alveolar cells with adherent pneumocysts appear vacuolated and eroded. However, studies of cultured lung epithelial cells have shown that the adherence of pneumocystis alone does not disrupt the structure or barrier function of alveolar epithelial cells, though proliferative repair of the epithelium is reduced. It is therefore unlikely that the adherence of pneumocystis to alveolar epithelium is by itself responsible for the diffuse alveolar damage in severe pneumonia. Rather, the inflammatory responses in the host are primarily responsible for the compromise of the alveolar-capillary surface.

Electron microscopical studies have shown that pneumocystis organisms are embedded in protein-rich alveolar exudates, which contain abundant fibronectin, vitronectin, and surfactant proteins A and D. In contrast, surfactant protein B is reduced during pneumonia. Both surfactant protein A and surfactant protein D interact with the glycoprotein A components of the surface of pneumocystis. Surfactant protein A modulates the interactions of pneumocystis with the alveolar macrophages. In contrast, surfactant protein D mediates the aggregation of the pneumocystis organisms, but because the aggregated organisms are extremely poorly taken up by macrophages, many organisms may escape elimination. Pulmonary surfactant phospholipids, which contribute to the low surface tension in the alveoli, are reduced during pneumocystis pneumonia, and abnormalities in the composition and function of the surfactant are the result of the host’s inflammatory response to pneumocystis, rather than direct effects of the organisms on the surfactant components.

Pneumocystis pneumonia remains a serious cause of sickness and death in immunocompromised patients. The epidemiology of this infection is only beginning to emerge, but it includes the transmission of organisms between susceptible hosts as well as probable acquisition from environmental sources. Lung injury and respiratory impairment during pneumocystis pneumonia are mediated by marked inflammatory responses in the host to the organism. Trimethoprim–sulfamethoxazole with adjunctive corticosteroid therapy to suppress lung inflammation in patients with severe infection remains the preferred treatment. However, accumulating evidence of mutations of the gene that encodes dihydropteroate synthase in pneumocystis has aroused concern about the potential for the emergence of resistance to sulfa agents, which have been the mainstay of prophylaxis and treatment of pneumocystis pneumonia. An improved understanding of the basic biology of pneumocystis has helped to define new targets for the development of drugs to treat this important infection.

Supported by grants (RO1 AI-48409 to Dr. Thomas and RO1 HL 62150 and RO1 HL 55934 to Dr. Limper) from the National Institutes of Health. We are indebted to Pawan K. Vohra, Robert Vassallo, and Theodore J. Kottom for many helpful discussions.

**Summary**

Pneumocystis pneumonia remains a serious cause of sickness and death in immunocompromised patients. The epidemiology of this infection is only beginning to emerge, but it includes the transmission of organisms between susceptible hosts as well as probable acquisition from environmental sources. Lung injury and respiratory impairment during pneumocystis pneumonia are mediated by marked inflammatory responses in the host to the organism. Trimethoprim–sulfamethoxazole with adjunctive corticosteroid therapy to suppress lung inflammation in patients with severe infection remains the preferred treatment. However, accumulating evidence of mutations of the gene that encodes dihydropteroate synthase in pneumocystis has aroused concern about the potential for the emergence of resistance to sulfa agents, which have been the mainstay of prophylaxis and treatment of pneumocystis pneumonia. An improved understanding of the basic biology of pneumocystis has helped to define new targets for the development of drugs to treat this important infection.

Supported by grants (RO1 AI-48409 to Dr. Thomas and RO1 HL 62150 and RO1 HL 55934 to Dr. Limper) from the National Institutes of Health. We are indebted to Pawan K. Vohra, Robert Vassallo, and Theodore J. Kottom for many helpful discussions.


